IPP Bureau
Azenta obtains regulatory approval for clinical long-read whole genome sequencing test
By IPP Bureau - November 22, 2024
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI
By IPP Bureau - November 22, 2024
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Siegfried opens global R&D Center for Drug Substances in Switzerland
By IPP Bureau - November 21, 2024
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Emcure and MS Dhoni drive India’s fight against Anemia
By IPP Bureau - November 21, 2024
Emcure has launched an awareness campaign to help spread the word about male anemia
Informa Markets in India set to host 17th edition of CPHI & PMEC India Expo
By IPP Bureau - November 21, 2024
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development
By IPP Bureau - November 21, 2024
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors
By IPP Bureau - November 21, 2024
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Briefs: Jagsonpal Pharmaceuticals, Dr. Reddy’s Laboratories and Akums Drugs and Pharmaceuticals
By IPP Bureau - November 20, 2024
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules
By IPP Bureau - November 20, 2024
The product will be manufactured at Lupin’s Somerset facility in the US
Lupin launches Bumetanide Injection USP in US
By IPP Bureau - November 20, 2024
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Emcure Pharma’s SAKHI - Diabetes awareness program makes to Asia Book of Records
By IPP Bureau - November 20, 2024
Indegene announces new Center in Hyderabad
By IPP Bureau - November 20, 2024
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
CPHI India reports surge in exhibitor numbers
By IPP Bureau - November 20, 2024
Modernization and supply chain diversity drive new growth
DKSH and Abcam join forces to advance life science research in Vietnam
By IPP Bureau - November 19, 2024
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide
By IPP Bureau - November 19, 2024
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
